ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
ALNY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. ALNY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALNY is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ALNY had negative earnings in the past year.
ALNY had a positive operating cash flow in the past year.
In the past 5 years ALNY always reported negative net income.
In the past 5 years ALNY reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -7.90%, ALNY belongs to the best of the industry, outperforming 89.48% of the companies in the same industry.
With a Return On Equity value of -1026.96%, ALNY is not doing good in the industry: 82.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.9% | ||
| ROE | -1026.96% | ||
| ROIC | N/A |
ROA(3y)-22.27%
ROA(5y)-25.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 85.37%, ALNY belongs to the best of the industry, outperforming 88.59% of the companies in the same industry.
ALNY's Gross Margin has declined in the last couple of years.
ALNY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-3.18%
2. Health
2.1 Basic Checks
ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALNY has more shares outstanding than it did 1 year ago.
ALNY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALNY has an improved debt to assets ratio.
2.2 Solvency
ALNY has an Altman-Z score of 3.18. This indicates that ALNY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ALNY (3.18) is better than 76.47% of its industry peers.
ALNY has a debt to FCF ratio of 63.93. This is a negative value and a sign of low solvency as ALNY would need 63.93 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 63.93, ALNY belongs to the top of the industry, outperforming 92.34% of the companies in the same industry.
A Debt/Equity ratio of 31.64 is on the high side and indicates that ALNY has dependencies on debt financing.
The Debt to Equity ratio of ALNY (31.64) is worse than 84.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 31.64 | ||
| Debt/FCF | 63.93 | ||
| Altman-Z | 3.18 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
ALNY has a Current Ratio of 2.75. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.75, ALNY is not doing good in the industry: 67.20% of the companies in the same industry are doing better.
ALNY has a Quick Ratio of 2.69. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a Quick ratio of 2.69. This is in the lower half of the industry: ALNY underperforms 67.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.71% over the past year.
ALNY shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.54%.
ALNY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 89.46% yearly.
EPS 1Y (TTM)36.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.65%
Revenue 1Y (TTM)21.54%
Revenue growth 3Y54.8%
Revenue growth 5Y89.46%
Sales Q2Q%-33.26%
3.2 Future
ALNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.96% yearly.
Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 21.28% on average per year.
EPS Next Y46.21%
EPS Next 2Y29.4%
EPS Next 3Y39.88%
EPS Next 5Y40.96%
Revenue Next Year22.75%
Revenue Next 2Y19.91%
Revenue Next 3Y24.73%
Revenue Next 5Y21.28%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALNY. In the last year negative earnings were reported.
Also next year ALNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
92.16% of the companies in the same industry are more expensive than ALNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1988.03 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALNY's earnings are expected to grow with 39.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.4%
EPS Next 3Y39.88%
5. Dividend
5.1 Amount
No dividends for ALNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALNYLAM PHARMACEUTICALS INC
NASDAQ:ALNY (11/21/2024, 8:11:53 PM)
After market: 246.8 0 (0%)246.8
-1.99 (-0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap31.83B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.9% | ||
| ROE | -1026.96% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 31.64 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)36.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y46.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.54%
Revenue growth 3Y54.8%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y